Use of anti-parkinson agents**	Yes	61	9.9%	64	13.5%	0.084^F)	17	5.5%	33	12.3%	0.005^F)	44	14.5%	31	15.0%	0.899^F)
Use of anti-parkinson agents**	No	553	90.1%	411	86.5%	0.084^F)	293	94.5%	235	87.7%	0.005^F)	260	85.5%	176	85.0%	0.899^F)
Use of antidepressants**	Yes	29	4.7%	33	6.9%	0.146^F)	17	5.5%	14	5.2%	1.000^F)	12	3.9%	19	9.2%	0.022^F)
Use of antidepressants**	No	585	95.3%	442	93.1%	0.146^F)	293	94.5%	254	94.8%	1.000^F)	292	96.1%	188	90.8%	0.022^F)
Use of anti-anxiety/sleep agents**	Yes	273	44.5%	234	49.3%	0.126^F)	139	44.8%	124	46.3%	0.738^F)	134	44.1%	110	53.1%	0.048^F)
Use of anti-anxiety/sleep agents**	No	341	55.5%	241	50.7%	0.126^F)	171	55.2%	144	53.7%	0.738^F)	170	55.9%	97	46.9%	0.048^F)
Use of antiepileptic agents**	Yes	81	13.2%	70	14.7%	0.480^F)	45	14.5%	34	12.7%	0.546^F)	36	11.8%	36	17.4%	0.092^F)
Use of antiepileptic agents**	No	533	86.8%	405	85.3%	0.480^F)	265	85.5%	234	87.3%	0.546^F)	268	88.2%	171	82.6%	0.092^F)
Use of mood-stabilizers**	Yes	16	2.6%	12	2.5%	1.000^F)	4	1.3%	7	2.6%	0.361^F)	12	3.9%	5	2.4%	0.454^F)
Use of mood-stabilizers**	No	598	97.4%	463	97.5%	1.000^F)	306	98.7%	261	97.4%	0.361^F)	292	96.1%	202	97.6%	0.454^F)